Volume 7 Issue 184
Published - 14:00 UTC 08:00 EST 3-Jul-2005 
Next Update - 14:00 UTC 08:00 EST 4-Jul-2005

Editor: Susan K. Boyer, RN
© Vidyya.
All rights reserved.

We subscribe to the HONcode principles. Verify here.

  

 


Poly/mono balance important to cholesterol-lowering diet

In the search for the best fats for a heart healthy diet, trans- and saturated fats have long been recognized as undesirable and those that contain polyunsaturated fatty acids (PUFAs) and mono-unsaturated fatty acids (MUFAs) are preferred -- with no clear benefit demonstrated for higher levels of either the PUFAs or the MUFAs within recommended limits. more  

One-drug therapy works for bipolar disorder

For the first time, researchers have demonstrated in separate short-term trials that a single drug therapy may be effective in treating both the manic and depressive phases of bipolar disorder. The condition (bipolar I and II) affects approximately 8 million Americans, who have relied on a combination of drugs to manage their symptoms, and who remain at high risk of committing suicide because of the difficulty in treating the disorder. more

Eliminating bacterial infections out of thin air

When microorganisms invade the body, immune mechanisms kick in to fight them off. The infected tissues typically show depleted oxygen levels, and a protein called HIF-1 alpha regulates this. Interestingly, the cells responsible for destroying the foreign pathogens are effective in this low-oxygen environment. more  

Muscles in obesity have problems choosing fuel

In obese and diabetic people, fat and carbohydrate oxidation by skeletal muscle is disrupted, contributing to insulin resistance. In a new study appearing in the July 1 print issue of The Journal of Clinical Investigation, Barbara Ukropcova and colleagues from Pennington Biomedical Research Center examine whether the ability of skeletal muscle to oxidize fat in vitro is representative of the donor's metabolic characteristics. more

New drug is effective in reducing rejection in heart transplantation  

A new study shows that a drug, called daclizumab, is effective at reducing organ rejection and risk of infection in heart transplant patients. The multi-center study by cardiologists from the United States, Sweden, Germany and Canada will be published in the June 30 issue of The New England Journal of Medicine. more

Prescribing information: Zenapax (daclizumab)  

Daclizumab belongs to a group of medicines known as immunosuppressive agents. It is used to lower the body's natural immunity in patients who receive kidney transplants. When a patient receives a kidney transplant, the body's white blood cells will try to get rid of (reject) the transplanted kidney. Daclizumab works by preventing the white blood cells from getting rid of the transplanted kidney. The effect of daclizumab on the white blood cells may also reduce the body's ability to fight infections. more

Scientists uncover clues to “disappearing” precancers

New research sheds light on why cervical precancers disappear in some women and not in others. Scientists at the Johns Hopkins Kimmel Cancer Center say the reason many of these lesions persist is an unlikely mix of human papilloma virus (HPV) strain and a woman’s individual immune system. more

 

Daclizumab is effective at reducing organ rejection and risk of infection in heart transplant patients.